At a glance
ClinicalIndex Comparison RecordN/ACompleted· 809 enrolled
Drug / intervention
DESTINEXother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA
In Brief
An observational study evaluating DESTINEX for Gastric Cancer and 18 related conditions. Completed, enrolled 809 participants across 3 sites in 2 countries.
Detailed Summary
Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Gastric Adenocarcinoma, Gastric Cancer Stage, Gastric Neoplasm, Gastric Lesion, Gastric Cancer in Situ, Gastric Cancer Stage IV, Gastric Cancer Stage IIIB, Gastric Cancer Stage III, Gastric Cancer Stage IB, Gastric Cancer Stage IA, Gastric Cancer, Stage 0, Gastric Cancer Stage IIIA, Gastric Cancer Stage II, Gastric Cancer TNM Staging, Gastric Cancer Metastatic to Lung, Gastric Cancer Metastatic to Liver, Gastric Cancer Stage I, Gastric Cancer TNM Staging Primary Tumor (T) T2B
CountriesJapan, United States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartMar 2023
First PostedApr 2024
Primary CompletionJun 2024
TodayJul 2026
First PostedApr 2, 2024
Enrollment StartMar 15, 2023
Primary CompletionJun 15, 2024
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 2.2 years ago
Interventions
DESTINEXother
A panel of microRNA, whose expression level is tested in serum samples.